癌症研究档案

  • 国际标准期刊号: 2254-6081
  • 期刊 h 指数: 13
  • 期刊引用分数: 3.58
  • 期刊影响因子: 3.12
索引于
  • 中国知网(CNKI)
  • 引用因子
  • OCLC-WorldCat
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • 秘密搜索引擎实验室
分享此页面

抽象的

State of the Science in Radiation Oncology and Priorities for Clinical Trials Meeting Report from the European Organization for Research and Treatment of Cancer

Barley Jamish

New technologies and techniques in radiation medical specialty and imaging supply opportunities to reinforce the good thing about loco-regional treatments expand treatment to new patient populations like those with oligometastatic unwellness and reduce traditional tissue toxicity. Moreover, novel agents became obtainable which can be combined with actinotherapy, and identification of radiation-related biomarkers is studied to refine treatment prescriptions. Finally, the utilization of AI (AI) capabilities can also improve treatment quality assurance or the benefit with that radiation dosing is prescribed. All of those potential advances gift each opportunities and challenges for educational clinical researchers. Recently, the Organisation for analysis and Treatment of Cancer addressed these topics in an exceedingly meeting of multiple stakeholders from Europe and North America. the subsequent 5 themes radiobiology-based biomarkers, new technologies – significantly nucleon beam medical aid, combination general and actinotherapy, management of oligometastatic unwellness and AI opportunities in radiation medical specialty were mentioned in an exceedingly State of Science format to outline key controversies, nonreciprocal queries and propose run priorities for development.

Keywords

Cytoreductive surgery; Peritoneal metastases mitomycin C; Hyperthermia; Radical appendectomy

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证